Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2006 1
2014 1
2015 2
2017 1
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Erdheim-Chester disease.
Haroche J, Cohen-Aubart F, Amoura Z. Haroche J, et al. Blood. 2020 Apr 16;135(16):1311-1318. doi: 10.1182/blood.2019002766. Blood. 2020. PMID: 32107533 Free article. Review.
Some of the most striking signs of ECD are the long bone involvement (80%-95%), as well as the hairy kidney appearance on computed tomography scan (63%), the coated aorta (40%), and the right atrium pseudo-tumoral infiltration (36%). Central nervous system involvement is a strong …
Some of the most striking signs of ECD are the long bone involvement (80%-95%), as well as the hairy kidney appearance on computed tomograph …
Erdheim-Chester disease.
Campochiaro C, Tomelleri A, Cavalli G, Berti A, Dagna L. Campochiaro C, et al. Eur J Intern Med. 2015 May;26(4):223-9. doi: 10.1016/j.ejim.2015.03.004. Epub 2015 Apr 10. Eur J Intern Med. 2015. PMID: 25865950 Free article. Review.
Cardiovascular and central nervous system (CNS) involvement are associated with the worst prognosis. Biopsy is necessary to establish a definite diagnosis with the identification of CD68+/CD1a-/S100- foamy histiocytes. ...
Cardiovascular and central nervous system (CNS) involvement are associated with the worst prognosis. Biopsy is necessary to establish …
Cardiovascular manifestations of Erdheim-Chester disease.
Berti A, Ferrarini M, Ferrero E, Dagna L. Berti A, et al. Clin Exp Rheumatol. 2015 Mar-Apr;33(2 Suppl 89):S-155-63. Epub 2015 Feb 18. Clin Exp Rheumatol. 2015. PMID: 25738753 Review.
Cardiovascular involvement affects more than 20% of patients and associates with poor prognosis, conferring a reduced response to treatment. Frequent findings are pericardial effusion (24% of patients), "coated aorta", a perivascular circumferential thickening of the aorta …
Cardiovascular involvement affects more than 20% of patients and associates with poor prognosis, conferring a reduced response to tre …
Imaging in Erdheim-Chester disease: classic features and new insights.
Moulis G, Sailler L, Bonneville F, Wagner T. Moulis G, et al. Clin Exp Rheumatol. 2014 May-Jun;32(3):410-4. Epub 2014 Jan 14. Clin Exp Rheumatol. 2014. PMID: 24428974 Review.
Fluorodeoxyglucose Positron Emission Tomography in the diagnosis or prognosis assessment is still discussed. The objective of this review is to discuss the place of each imaging technique in Erdheim-Chester disease in 2013....
Fluorodeoxyglucose Positron Emission Tomography in the diagnosis or prognosis assessment is still discussed. The objective of this re …
"Coated aorta": a new sign of Erdheim-Chester disease.
Serratrice J, Granel B, De Roux C, Pellissier JF, Swiader L, Bartoli JM, Disdier P, Weiller PJ. Serratrice J, et al. J Rheumatol. 2000 Jun;27(6):1550-3. J Rheumatol. 2000. PMID: 10852289
Variability in the efficacy of interferon-alpha in Erdheim-Chester disease by patient and site of involvement: results in eight patients.
Haroche J, Amoura Z, Trad SG, Wechsler B, Cluzel P, Grenier PA, Piette JC. Haroche J, et al. Arthritis Rheum. 2006 Oct;54(10):3330-6. doi: 10.1002/art.22165. Arthritis Rheum. 2006. PMID: 17009306 Free article. Clinical Trial.
ECD features heterogeneous systemic manifestations, and the general prognosis remains poor despite various treatment options. METHODS: We treated 8 patients with multisystemic ECD with subcutaneous interferon-alpha (IFNalpha) at a dosage of 3-9 x 10(6) units 3 times weekly …
ECD features heterogeneous systemic manifestations, and the general prognosis remains poor despite various treatment options. METHODS …